Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid
carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which
decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to
improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate
the effectiveness of alpha-lipoic acid (ALA) for improving I-131 uptake in recurrent or
metastatic of DTC with defective I-131 uptake.